SalaryGuide
AboutPricingBlogFor Employers

Marketing jobs

5 marketing jobs

Chiesi Group logo
8 days ago

Sr. Manager, Digital Marketing Asset & Content Governance

Chiesi Group

Boston, MA (Hybrid)Full time$161K/yr – $197K/yr
Chiesi Group logo
4 weeks ago

Lead, Payer Marketing & Strategy, Global Rare Diseases

Chiesi Group

Boston, MA (Hybrid)Full time$184K/yr – $225K/yr
Chiesi Group logo
4 weeks ago

HCP Marketing Lead, HAE, Global Rare Diseases

Chiesi Group

Boston, MA (Hybrid)Full time$210K/yr – $245K/yr
Chiesi Group logo
5 months ago

Lead, Omnichannel Marketing

Chiesi Group

Cary, NC (Hybrid)Full time
Chiesi Group logo
6 months ago

Marketing Operations Specialist, Global Rare Diseases

Chiesi Group

Boston, MA (Hybrid)Full time$93K/yr – $114K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

5 jobs
Chiesi Group logo

Sr. Manager, Digital Marketing Asset & Content Governance

Chiesi Group

Boston, MA (Hybrid)

$161K/yr - $197K/yrIn-houseFull-timeSenior level5+ years exp.
8 days ago
Chiesi Group logo

Lead, Payer Marketing & Strategy, Global Rare Diseases

Chiesi Group

Boston, MA (Hybrid)

$184K/yr - $225K/yrIn-houseFull-timeSenior level
4 weeks ago
Chiesi Group logo

HCP Marketing Lead, HAE, Global Rare Diseases

Chiesi Group

Boston, MA (Hybrid)

$210K/yr - $245K/yrIn-houseFull-timeSenior level10+ years exp.
4 weeks ago
Chiesi Group logo

Lead, Omnichannel Marketing

Chiesi Group

Cary, NC (Hybrid)

In-houseFull-timeSenior level7+ years exp.
5 months ago
Chiesi Group logo

Marketing Operations Specialist, Global Rare Diseases

Chiesi Group

Boston, MA (Hybrid)

$93K/yr - $114K/yrIn-houseFull-timeMid level5+ years exp.
6 months ago
Chiesi Group logo
Chiesi Group

Sr. Manager, Digital Marketing Asset & Content Governance

Boston, MA (Hybrid)

$161K/yr – $197K/yrSenior Level5+ years expFull time

Posted 8 days ago

  • Job
  • Company
  • Salaries
  • People
  • Audience
  • News
  • Links

Job Summary

Own governance of US Rare assets, metadata standards, and lifecycle across DAM and the Claims Library; drive adoption, audits readiness, and data-driven improvements.

  • Sets metadata standards, compliance gates, and governance cadence.
  • Drives adoption through training, playbooks, and champion networks.
  • Turns analytics into action with dashboards on reuse and metadata quality.

Job Description

Responsibilities

  • Own governance for US Rare across DAM and the Claims Library—define metadata/taxonomy standards and controlled vocabularies.
  • Ensure claims traceability for every asset/module (source IDs, version lineage, rights/consent, expiry).
  • Run the lifecycle from creation → approval → reuse → deprecation/archive, with automated checks and alerts.
  • Be the compliance gate with Regulatory/Medical/Privacy; prepare for audits and quickly remediate findings.
  • Drive adoption —deliver training, playbooks, office hours, and a champion network so teams actually use the standards.
  • Improve findability & reuse —QA ingestion/tagging, partner with brand teams and agencies, and reduce rework.
  • Enable modular content —ensure components are structured/tagged for reuse and localization.
  • Make the data useful —publish dashboards on reuse, cycle time, and metadata quality; turn insights into actions with Analytics.
  • Manage vendors/SLA work —lead offshore/onshore tagging backlogs, set acceptance criteria, and audit quality.
  • Continuously improve —run quarterly governance reviews, refine policies, and help design the future run-state with Marketing Ops.

Requirements

  • 5+ years in DAM/content governance or content operations (regulated industry preferred).
  • Strong metadata/taxonomy design and content lifecycle management experience.
  • Working knowledge of claims management, usage rights/consent, and audit requirements.
  • Experience with enterprise DAM and medical/legal/review systems (e.g., Veeva PromoMats or similar).
  • Proven training and change-management chops—comfortable leading adoption across teams.
  • Data literacy—can define/report KPIs (reuse rate, cycle time, metadata completeness) using Excel/BI.
  • Vendor/agency management experience; comfortable coordinating offshore support.
  • Bachelor’s degree or equivalent experience; library science, information management, or similar a plus.

Benefits

  • No matter where your path starts at Chiesi, it leads to inspiring possibilities. Your future is our focus, and we are committed to nurturing your development in our dynamic, friendly environment with access to resources and training every step of the way.
  • We provide top-class benefits, including comprehensive healthcare programs, work-life balance initiatives, and robust relocation support.
  • Our salary package is competitive, comprising a basic salary, performance bonuses, and benefits benchmarked against the external market.
  • Additionally, we offer flexible working arrangements, remote work options, and tax assistance services for foreign colleagues, all designed to help you thrive.
Chiesi Group logo

Chiesi Group

4.1 Glassdoor

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy, the US, France and Colombia, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. With 90 years of experience, Chiesi is headquartered in Parma (Italy), with more than 30 affiliates worldwide, and counts more than 7,500 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.For further information please visit www.chiesi.com

Founded in 1935
Parma, Emilia-Romagna, ITA
6K employees (342 in marketing)
www.chiesi.com
84% recommend to a friend
91% CEO approval

Salaries

Posted range

$161K/yr – $197K/yr

Taken straight from the job posting.

See all Chiesi Group salaries

Marketing Team

Marketing Team Size
221 (4% of company)
Median Career Experience
24 years
Median Tenure
4.2 years
Marketing Roles Posted (Last 30 Days)
3

People

HR / Recruitment

Marco Camin
Marco Camin
Head of Global People Tech & Data Insights
At the company for 9 years 5 months
Emanuele Longhin
Emanuele Longhin
Qualifica Group HR Analytics and HRIS Specialist
At the company for 3 years 1 month

Traffic Signals

Monthly Visitors
74.4K
Traffic Source Mix
Search
45.6%
Direct
37.3%
Referral
9.1%
Social
6.6%
Paid
1%

Headcount Trend

Current headcount: ~6K

Recent News

Rigenerazione urbana a Parma. Il polo farmaceutico di Chiesi diventa un giardino culturale
Oct 13, 2025 • Artribune
Chiesi entra nel gene editing per le malattie renali rare con Arbor Biotechnologies
Oct 8, 2025 • Daily Health Industry
Chiesi e Plug and Play alla ricerca di startup europee per la terapia neonatale. Ecco come candidarsi
Oct 7, 2025 • StartupItalia
Chiesi sigla partnership con americana Arbor Biotechnologies: intesa su nuovi programmi di "gene editing" per le malattie rare
Oct 6, 2025 • Gazzetta di Parma
Gruppo Chiesi, il centro ricerche intitolato a Paolo Chiesi - Video
Oct 4, 2025 • Gazzetta di Parma
Gruppo Chiesi: intitolato a Paolo il Centro Ricerche
Oct 3, 2025 • ParmaToday
Fondazione Chiesi, un nuovo nome e una grande sfida
Sep 26, 2025 • Gazzetta di Parma
IgA Nephropathy Treatment Market to Hit $3.24 Billion by 2033, Fueled by ACE Inhibitors & Novel Therapies
Sep 26, 2025 • EIN Presswire
With FDA Nod in Rare Hormone Disease, Crinetics Can Challenge Blockbuster Meds From Novartis, Ipsen
Sep 26, 2025 • MedCity News
Idebenone Accepted by FDA for Priority Review for Leber Hereditary Optic Neuropathy (LHON)
Sep 22, 2025 • Chiesi Global Rare Diseases
Michele Zappoli nominato Senior Clinical Project Manager in Chiesi
Sep 17, 2025 • IMille protagonisti del mondo economico
Chiesi, nel primo semestre ricavi in crescita a 1,86 mld (+13,2%)
Sep 16, 2025 • Seguonews
Chiesi accelera sulla crescita sostenibile: ricavi a 1,86 miliardi nel primo semestre 2025
Sep 16, 2025 • Farmacista33
DKSH and Chiesi Asian progress ‘a new precedent’ for rare disease approvals
Sep 16, 2025 • Pharma Letter
Stage Chiesi Farmaceutici per studenti e laureati, compenso 1000 Euro al mese
Sep 10, 2025 • Ti Consiglio un Lavoro
Chiesi Global Rare Diseases Highlights Continued Commitment to Rare Disease Community at the International Congress of Inborn Errors of Metabolism (ICIEM) 2025
Sep 9, 2025 • Morningstar.com
Global drugmakers face tougher competition with local rivals in Russia
Sep 4, 2025 • Pharma Letter
PDE4B Inhibitor Market Poised for Strong Growth by 2034 | DelveInsight
Sep 3, 2025 • DelveInsight Business Research LLP
Chiesi wins long-awaited NICE nod for idebenone in LHON
Aug 7, 2025 • Pharma Letter
Cystinosis Global Market Research Report 2025-2035 | Orphan Drug Incentives, Innovative Cysteamine Delivery, Gene Therapy Potential, and Early Diagnosis Fueling Advancements
Aug 5, 2025 • Research and Markets
Chiesi Group e Serna Bio insieme per terapie respiratorie innovative
Aug 1, 2025 • FarmaciaVirtuale.it
INHALED AMINOGLYCOSIDE FORMULATIONS Market to Surpass $350 Million by 2025
Jul 28, 2025 • PRLog
Fabry Disease Market Analysis, Key Company Profiles, Product Portfolio, Pipeline Product Analysis, Recent Developments and Dynamics 2025-2030 - ResearchAndMarkets.com
Jul 25, 2025 • Business Wire
Chiesi collaborates with Serna Bio on respiratory diseases
Jul 24, 2025 • Pharma Letter
Protalix BioTherapeutics Appoints Gilad Mamlok as SVP and CFO
Jul 21, 2025 • citybiz
Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer
Jul 21, 2025 • PR Newswire
Fabry Disease Treatment Analysis Report 2025 | Market to Reach $3.86 Billion by 2030, Rising Fabry Disease Prevalence and Demand for Targeted Therapies Drive Growth
Jul 18, 2025 • Research and Markets
Serial dealmaker Cathal Friel: ‘It’s important not to hand easy money to the next generation’
Jul 18, 2025 • Irish Times
Breathing Innovation Challenge Aims to Advance Respiratory Care
Jul 17, 2025 • TechAcute
autologous cell therapy product market
Jul 15, 2025 • PharmiWeb
Asthma and COPD Drugs Market 2025: Strategic Insights for Growth, Expansion, and Gaining Competitive Edge
Jul 4, 2025 • EIN Presswire
bronchopulmonary dysplasia treatment market
Jul 3, 2025 • PharmiWeb
Leading Driver In The Lysosomal Enzyme Market 2025: Rising Healthcare Expenditure Fuels Growth In Therapy (ERT) Market
Jul 1, 2025 • EIN Presswire
Iron Chelation Therapy Market Report 2025 – Insights For Companies Seeking Expansion, Growth & Competitive Advantage
Jun 30, 2025 • EIN Presswire
Lavoro: Chiesi Farmaceutici è l’azienda più attrattiva nella farmaceutica
Jun 20, 2025 • ParmaToday
Global Pneumoconiosis Market To Reach $7.62 Billion By 2029 With A Growth Rate Of 8.0%.
Jun 19, 2025 • EIN Presswire
Chiesi Group rafforza il team legale con la nomina di Camilla Broggini come Lead Legal Counsel & Group Compliance Officer per Air&Care
Jun 17, 2025 • IMille protagonisti del mondo economico
Fabry Disease Market Analysis 2025 – Insights For Long-Term Investment & Planning
Jun 16, 2025 • EIN Presswire
Redefining Fabry Disease Care: Gene Therapy and Long-Acting ERT Prepare to Disrupt Status Quo | Competitive Intellignece
Jun 15, 2025 • EIN Presswire
Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders
Jun 12, 2025 • BioSpace
Gaucher and Pompe diseases enzyme replacement therapy (ERT) market
Jun 12, 2025 • PharmiWeb
Chiesi partners with Key2Brain to develop therapies for rare neurodegenerative diseases
Jun 12, 2025 • Pharmafile
Farmaceutica. Chiesi punta a 6 miliardi di euro di ricavi entro il 2030
Jun 11, 2025 • Farmacista33
Chiesi Group sigla un accordo di licenza mondiale con Key2Brain AB per promuovere terapie che attraversano la barriera ematoencefalica per le malattie da accumulo lisosomiale
Jun 11, 2025 • Adnkronos
Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders
Jun 11, 2025 • Chiesi Group
Chiesi enters deal to leverage Key2Brain’s technology
Jun 11, 2025 • Pharma Letter
Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders
Jun 11, 2025 • Chiesi Group
Study into treatment for rare condition in premature infants launches globally
Jun 9, 2025 • Pharmafile
Italy's Chiesi Group plans acquisitions to boost sales to 6 billion euros by 2030
Jun 5, 2025 • Reuters
Farmaceutica. Chiesi presenta il Bilancio di Sostenibilità 2024: anno di evoluzione e impatto positivo
Jun 4, 2025 • Farmacista33
Neurotrophic Keratitis Treatment Market Report 2025: $22.6 Bn Opportunities and Strategies to 2034 - Recombinant Human Nerve Growth Factor Segment Tops Neurotrophic Keratitis Treatments
Jun 3, 2025 • Research and Markets
The Global Triple Combination Therapy Market: Key Drivers, Trends, Growth Opportunities, And Forecast 2025-2034
May 29, 2025 • EIN Presswire
Leber Hereditary Optic Neuropathy Treatment Market Forecast 2025–2034: Insights on Market Size, Trends & Competition
May 28, 2025 • EIN Presswire
Gruppo Chiesi, Esposito nuovo vice president global internal audit
May 18, 2025 • TopLegal
Chiesi, Federico Esposito nominato VP global internal audit
May 13, 2025 • Inhousecommunity
Federico Esposito è il nuovo Vice President Global Internal Audit di Chiesi
May 13, 2025 • IMille protagonisti del mondo economico
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™
Apr 24, 2025 • PR Newswire
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™
Apr 24, 2025 • PR Newswire UK
Chiesi chiude il 2024 con una crescita a doppia cifra e punta sull’innovazione per il futuro
Apr 16, 2025 • Farmacista33
Gruppo Chiesi acquisisce un nuovo sito produttivo a Nerviano. Gop e Chiomenti gli studi coinvolti
Apr 9, 2025 • Legalcommunity
Il Gruppo Chiesi rilancia l'ex stabilimento Carlo Erba a Nerviano: "Segnale di fiducia nelle potenzialità del Comune"
Apr 1, 2025 • LegnanoNews
Gruppo Chiesi: 300 assunzioni con nuovo stabilimento a Nerviano (Milano)
Mar 31, 2025 • Ti Consiglio un Lavoro
A mezz'ora da Como nasce il nuovo stabilimento da 430 milioni del colosso farmaceutico. E assume 300 persone
Mar 30, 2025 • ComoZero
Gruppo Chiesi apre un nuovo polo produttivo nel Milanese (e assumerà 300 persone)
Mar 27, 2025 • milanotoday.it
Il Gruppo Chiesi investe a Nerviano: 300 posti di lavoro nell’ex stabilimento della Carlo Erba
Mar 27, 2025 • SaronnoNews
Chiesi acquista il sito produttivo di Nerviano (MI) per 430 milioni | Fedaiisf Federazione delle
Mar 27, 2025 • Fedaiisf
Chiesi compra un nuovo stabilimento a Nerviano: investimento da 430 milioni di euro
Mar 27, 2025 • Forbes Italia
Farmaceutica, Chiesi investe in un nuovo stabilimento a Nerviano
Mar 27, 2025 • Farmacista33
Nerviano, il futuro è negli inalatori: investimento da 430 milioni del gruppo Chiesi, in arrivo 300 posti di lavoro
Mar 27, 2025 • Il Giorno
Pharma, Chiesi investe 430 milioni di euro per un nuovo polo produttivo a Nerviano (Milano)
Mar 27, 2025 • Milano Finanza
Chiesi investe 430 milioni per trasformare il polo di Nerviano in un centro di eccellenza farmaceutica
Mar 27, 2025 • Il Sole 24 ORE
Chiesi Acquires New Manufacturing Site in Nerviano (Milan) with a Strategic €430 Million Investment To 2030 to Drive Global Growth
Mar 27, 2025 • PharmiWeb
Global Heterozygous Familial Hypercholesterolemia Management Market Forecast 2025-2034: Analyzing Growth
Mar 26, 2025 • EIN Presswire
Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025
Mar 24, 2025 • PR Newswire
Ignazio Davide Messina nominato Lead Legal Counsel di Chiesi per innovazione e protezione
Mar 12, 2025 • IMille protagonisti del mondo economico
Chiesi, Messina diventa lead legal counsel, global legal business, innovation & protection
Mar 12, 2025 • Inhousecommunity
Top Growth Driver In The Lamzede Market 2025: Rising Prevalence Of Rare Genetic Disorders Driving The Market Growth
Mar 8, 2025 • EIN Presswire
Leading Factor Driving The Neonatal Respiratory Distress Syndrome Treatment Market In 2025:
Feb 27, 2025 • EIN Presswire
Cystic Fibrosis Market: Trends, Insights, and Growth Projections 2025-2035
Feb 20, 2025 • PharmiWeb.com
Riccardo Spagnoli promosso Senior Director Global Privacy di Chiesi Group
Feb 17, 2025 • IMille protagonisti del mondo economico
Chiesi, Riccardo Spagnoli nominato senior director global privacy
Feb 17, 2025 • Inhousecommunity
Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Size to Reach USD 7,463.5 Million by 2035, Impelled by Advancements in Diagnostic Technologies
Feb 14, 2025 • BioSpace
Patients as Partners® Europe Launches the 9th Annual Event with 2025 Keynotes, Featured Speakers and Topics
Feb 11, 2025 • EuropaWire
Tre nuovi consiglieri nel Cda di Chiesi
Jan 29, 2025 • BeautyBiz
Chiesi Farmaceutici nomina tre nuovi amministratori indipendenti nel suo CdA
Jan 29, 2025 • AboutPharma
Daphne Quimi entra nel CdA di Chiesi: nuovo slancio alla governance internazionale
Jan 29, 2025 • IMille protagonisti del mondo economico
Key Trend Shaping the Myalept Market in 2025: Regulatory Approvals Driving Accessibility And Advancements In The Market
Jan 29, 2025 • EIN Presswire
Global lamzede Market Forecast: Key Growth Drivers, Trends, and Opportunities from 2025 to 2034
Jan 29, 2025 • EIN Presswire
Phosphodiesterase-4 (PDE4) Inhibitor Market Projected to Grow at a Strong CAGR from 2020 to 2034 by DelveInsight
Dec 5, 2024 • EIN Presswire
Nephropathic Cystinosis Treatment Market Poised to Reach Over US$ 744 Million by 2034 | Transparency Market Research
Dec 2, 2024 • GlobeNewswire News Room
Groundbreaking Insights Unveiled in Non-Cystic Fibrosis Bronchiectasis Pipeline Report
Nov 28, 2024 • GlobeNewswire News Room
Fra le 25 migliori aziende del mondo c’è anche un’italiana, il Gruppo Chiesi di Parma
Nov 16, 2024 • QuiFinanza
Chiesi è la prima azienda italiana nella classifica World’s Best Workplaces
Nov 14, 2024 • Farmacista33
Cystic Fibrosis Market Size to be Worth USD 55.4 Billion by 2032, with a Projected CAGR of 21.6%
Nov 12, 2024 • EIN Presswire

Links

www.chiesi.comLinkedInX (Twitter)Crunchbase